Targeting high Aurora kinases expression as an innovative therapy for hepatocellular carcinoma

Oncotarget. 2017 Apr 25;8(17):27953-27965. doi: 10.18632/oncotarget.15853.

Abstract

The Aurora kinases A and B control tumorigenesis by inhibiting apoptosis and promoting proliferation and metastasis, however, it remains unknown whether Aurora A and B overexpressed concomitantly and its clinical significance in hepatocellular carcinoma (HCC). Here, we obsearved Aurora A and B tended to overexpress parallelly on protein level (r = 0.8679, P < 0.0001) and their co-overexpression (Aurora AHBH), associated with the worst prognosis, was an independent predictor for the survival. Importantly, with the lower IC50 and stronger anti-tumor effect than selective inhibitors, SNS-314, the pan-inhibitor of Aurora kinases, which induced YAP (Yes-associated protein) reduction and resulted in P21 accumulation, significantly promoted the polyploidy (> 4N) formation and apoptosis in HCC. High YAP expression (YAPH) was associated with Aurora AHBH, and appeared to be an independent predictor for survival, but P21 not. Moreover, silencing YAP also induced P21 accumulation, and knockdown P21, which enhanced YAP accumulation and weakened the SNS-314-induced YAP reduction, impaired SNS-314-induced apoptosis. Therefore, P21 enhanced the apoptotic effect of SNS-314 in HCC. Taken together, our findings indicated Aurora kinases/YAP/P21 was an oncogenic signaling axis in HCC, and revealed targeting Aurora AHBH induced apoptosis by YAP suppression. Our results also provided a solid evidence for SNS-314 as a potential targeted therapy, and a proof-of-concept evidence for a possible combined therapy of SNS-314 plus Hippo pathway inhibitors on HCC.

Keywords: Aurora A/B kinases; HCC; P21; SNS-314; YAP.

MeSH terms

  • Adult
  • Aged
  • Apoptosis / drug effects
  • Aurora Kinase A / genetics
  • Aurora Kinase A / metabolism
  • Aurora Kinase B / genetics
  • Aurora Kinase B / metabolism
  • Aurora Kinases / antagonists & inhibitors
  • Aurora Kinases / genetics
  • Aurora Kinases / metabolism*
  • Biomarkers, Tumor
  • Carcinoma, Hepatocellular / drug therapy
  • Carcinoma, Hepatocellular / genetics
  • Carcinoma, Hepatocellular / metabolism*
  • Carcinoma, Hepatocellular / mortality
  • Cell Cycle Proteins
  • Cell Line, Tumor
  • Cell Survival
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / genetics
  • Liver Neoplasms / metabolism*
  • Liver Neoplasms / mortality
  • Middle Aged
  • Models, Biological
  • Molecular Targeted Therapy
  • Nuclear Proteins / metabolism
  • Phenylurea Compounds / pharmacology
  • Polyploidy
  • Prognosis
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Thiazoles / pharmacology
  • Transcription Factors / metabolism
  • Tumor Burden

Substances

  • Biomarkers, Tumor
  • Cell Cycle Proteins
  • Nuclear Proteins
  • Phenylurea Compounds
  • Protein Kinase Inhibitors
  • SNS 314
  • Thiazoles
  • Transcription Factors
  • YY1AP1 protein, human
  • Aurora Kinase A
  • Aurora Kinase B
  • Aurora Kinases